8-K current report · filed Sep 3, 2026

Vaxcyte, Inc. (PCVX) 8-K Current Report: September 3, 2026

Item 5.02Item 7.01PCVX overview

Short answer

Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026.

Vaxcyte, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026
  • Mikhail Eydelman remains Senior Vice President and General Counsel
  • Expanded legal and compliance leadership may support regulatory execution as Vaxcyte advances its vaccine pipeline

Item 7.01 · Regulation FD Disclosure

  • Vaxcyte appointed a Chief Medical Officer and Chief Legal Officer, strengthening clinical-development and legal leadership
  • VAX-31 OPUS-1 topline data guidance narrowed, potentially improving timing visibility for investors
  • OPUS-1 topline results represent a key clinical catalyst for VAX-31 valuation and program risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vaxcyte, Inc. 8-K filings

Get the next PCVX 8-K as it lands

Follow PCVX for push alerts, or ask the research agent what this filing means.